Dendreon Corp fka DNDNQ

[croumagnon]

"a delay could make last year's $4.50 secondary pricing look good."

I disagree with that assessment although I realize I am in the minority here. Even if it became clear that approval will not come before at least the interim results of 9902b are tabulated, I think there is enough here to keep a bottom on the stock at or near $5. Even the negative UBS is now putting our price target at $4.5. I suspect we will soon find out that much of the short position has already covered and the stock will resume a modest upside until further news...The fact that we got such a strong endorsement by the advisory panel is a huge positive for the stock and even a delay of a couple of years will not justify much lower prices.